Sparks commentary - IRLAB Therapeutics

Healthcare

Sparks - IRLAB Therapeutics

More on this equity
IRLAB Therapeutics (OMX: IRLAB-A) receives US$2.5m milestone payment
Published by Arron Aatkar

IRLAB Therapeutics has received a US$2.5m milestone payment from the McQuade Center for Strategic Research and Development for dosing the first patient in a new Phase I trial with IRL757. This is the second clinical study for the candidate (the first is supported by The Michael J. Fox Foundation), and is focused on assessing the pharmacokinetics, safety and tolerability of single ascending oral doses of IRL757 in healthy individuals aged 65 and older. It is expected to conclude in late-Q424.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free